Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06799195 · ClinicalTrials.gov registry record · Phase 2
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
A Phase 2 study of Hematological Malignancies and Graft-versus-host Disease (GVHD), sponsored by University of Nebraska.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
- 1
- Study location
NCT06799195 is a Phase 2 study of Hematological Malignancies and Graft-versus-host Disease (GVHD) that is actively recruiting participants, run by University of Nebraska. The registered enrollment target is 126 participants, below the 769-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06799195, a Phase 2 study of Hematological Malignancies and Graft-versus-host Disease (GVHD), is actively recruiting participants, sponsored by University of Nebraska.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis among recipients of allogeneic hematopoietic stem cell transplant.
Conditions Studied
Interventions
- DRUG Sirolimus
- DRUG Attenuated-dose Cyclophosphamide
- DRUG High-dose Cyclophosphamide
- DRUG Mycophenolate Mofetil (MMF)
Study Locations (1)
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2025-06-23 |
| Est. Completion | 2031-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06799195
The ClinicalTrials.gov registry entry for NCT06799195 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 769-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (84% lower). The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematological Malignancies appearing as the primary indexed condition, and to 4 interventions - of which Sirolimus is the first listed.
NCT06799195 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT06799195 about?
NCT06799195 is a clinical study titled "Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation". This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis among recipients of allogeneic hematopoietic stem cell transplant.
What is the current status of trial NCT06799195?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2025-06-23. Estimated completion is 2031-11.
What conditions does trial NCT06799195 study?
This clinical trial studies the following conditions: Hematological Malignancies, Graft-versus-host Disease (GVHD).
What interventions are being tested in trial NCT06799195?
The interventions under investigation include: Sirolimus (DRUG), Attenuated-dose Cyclophosphamide (DRUG), High-dose Cyclophosphamide (DRUG), Mycophenolate Mofetil (MMF) (DRUG).
Who is sponsoring clinical trial NCT06799195?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06799195 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematological Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
COMPLETED · Phase 2
-
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
RECRUITING · Phase 1
-
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
RECRUITING
-
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.